Tugba Guven-Ozkan

Title: Tugba Guven-Ozkan: Innovator in Gene Therapy

Introduction

Tugba Guven-Ozkan is a notable inventor based in Plymouth Meeting, PA (US). She has made significant contributions to the field of gene therapy, particularly in the treatment of adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). Her work focuses on innovative approaches to address these serious medical conditions.

Latest Patents

Tugba Guven-Ozkan holds a patent for "AAV-ABCD1 constructs and use for treatment or prevention of adrenoleukodystrophy (ALD) and/or adrenomyeloneuropathy (AMN)." This patent relates to polynucleotides and AAV vectors that enable the expression of ALD protein in target cells, such as neurons or glial cells, when administered to subjects in need. The compositions described in her patent may be utilized for the treatment and prevention of ALD or AMN.

Career Highlights

Tugba Guven-Ozkan is currently associated with Swanbio Therapeutics Limited, where she continues to advance her research and development efforts. Her expertise in gene therapy has positioned her as a key figure in the fight against genetic disorders.

Collaborations

Throughout her career, Tugba has collaborated with notable colleagues, including Sean Clark and Karen Kozarsky. These partnerships have enhanced her research and contributed to the development of innovative therapeutic solutions.

Conclusion

Tugba Guven-Ozkan is a pioneering inventor whose work in gene therapy is making a significant impact on the treatment of genetic disorders. Her contributions are vital in advancing medical science and improving patient outcomes.